Evidence map›Paper›PMID 42839288›Full record

ArticleCritical care (London, England)2026

Polymyxin B hemoadsorption in endotoxic septic shock: ten questions on the Tigris trial.

Matthieu Legrand, Javier Neyra, George Tomlinson, John A Kellum

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Matthieu LegrandDepartment of Anesthesia and Perioperative Care, Division of Critical Care Medicine, University of California, 521 Parnassus Avenue, San Francisco, CA, 94143, USA. Matthieu.Legrand@ucsf.edu.
Javier NeyraDepartment of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
George TomlinsonDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
John A KellumDepartment of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Tigris trial recently reported that polymyxin B hemoadsorption (PMX) achieved a high posterior probability of benefit for mortality in adults with endotoxic septic shock (endotoxemia with multiple organ failure). The trial used a Bayesian framework with a prior derived from a subgroup of an earlier trial (EUPHRATES) and this subgroup was used to design eligibility criteria for Tigris. Ten questions that expose the trial's strengths and limitations are answered in this review. Writing as the trial investigators, our intention is to make the reasoning behind these decisions explicit, so that clinicians and trialists can judge what Tigris does, and does not, demonstrate.

Indexed as

HemoperfusionPolymyxin BShock, SepticAnti-Bacterial AgentsHumansAnti-Bacterial AgentsPolymyxin BBayesian trialEndotoxinExtracorporeal therapyHemoadsorptionHemoperfusionPolymyxin BPrecision medicineSeptic shock

Identifiers

PMID42839288
PMCPMC13644065

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.